Capital remains available for good healthtech projects, but it is more concentrated and harder to find than of late. Founders and inventors must know how to unlock it. The BioWales 2025 investor panel told them where they could be going wrong.
UK market conditions are currently challenging for technology inventors seeking their next injection of funding. But founders with validated projects that are presented in the right way can find success among investors looking to park their capital in healthtech.
That was view of Ali Lindsay, investments director at Maven Capital Partners, as she addressed BioWales 2025 from the conference’s...
Create an account to read this article
Already a subscriber?
A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.
China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.
Richard Wilson, SVP and primary focus lead for genetic regulation at Astellas, talks with In Vivo about the company's commitment to AAV as a gene therapy delivery vehicle, recent company investments and the regulatory environment under Trump's FDA.
